-
New Ypsilon and Ypsilon hf
-
The Cupra Raval will be launched in 2026
-
New id.Polo comes electric
-
Iran defies US threats to insist on right to enrich uranium
-
Seifert powers New Zealand to their record T20 World Cup chase
-
Naib's fifty lifts Afghanistan to 182-6 against New Zealand
-
Paul Thomas Anderson wins top director prize for 'One Battle After Another'
-
De Beers sale drags in diamond doldrums
-
NFL embraces fashion as league seeks new audiences
-
What's at stake for Indian agriculture in Trump's trade deal?
-
Real Madrid can wait - Siraj's dream night after late T20 call-up
-
Castle's monster night fuels Spurs, Rockets rally to beat Thunder
-
Japan votes in snow-hit snap polls as Takaichi eyes strong mandate
-
Pakistan's capital picks concrete over trees, angering residents
-
Berlin's crumbling 'Russian houses' trapped in bureaucratic limbo
-
Neglected killer: kala-azar disease surges in Kenya
-
Super Bowl set for Patriots-Seahawks showdown as politics swirl
-
Sengun shines as Rockets rally to beat NBA champion Thunder
-
Matsuyama grabs PGA Phoenix Open lead with Hisatsune one back
-
Washington Post CEO out after sweeping job cuts
-
Haiti's transitional council hands power to PM
-
N. Korea to hold party congress in February, first since 2021
-
Thailand votes after three leaders in two years
-
Swiss joy as Von Allmen wins first gold of Winter Olympics
-
George backs England to 'kick on' after Six Nations rout of Wales
-
Malinin upstaged as Japan keep pressure on USA in skating team event
-
Vail's golden comets Vonn and Shiffrin inspire those who follow
-
Veteran French politician loses culture post over Epstein links
-
Japan's Kimura wins Olympic snowboard big air gold
-
Arteta backs confident Gyokeres to hit 'highest level'
-
Hojlund the hero as Napoli snatch late win at Genoa
-
England's Arundell 'frustrated' despite hat-trick in Wales romp
-
Lollobrigida skates to first Italian gold of Winter Olympics on her birthday
-
Arundell hat-trick inspires England thrashing of Wales in Six Nations opener
-
Chile's climate summit chief to lead plastic pollution treaty talks
-
Rosenior hails 'unstoppable' Palmer after treble tames Wolves
-
French ex-minister offers resignation from Paris cultural hub over Epstein links
-
New NBA dunk contest champ assured and shooting stars return
-
Shiffrin says will use lessons learnt from Beijing flop at 2026 Games
-
Takaichi tipped for big win as Japan votes
-
Lens return top of Ligue 1 with win over Rennes
-
Shiffrin learning from Beijing lessons ahead of Milan-Cortina bow
-
Demonstrators in Berlin call for fall of Iran's Islamic republic
-
'Free the mountains!": clashes at Milan protest over Winter Olympics
-
Townsend accepts pressure will mount on him after Italy defeat
-
BMW iX3 new style and design
-
Suryakumar's 84 leads India to opening win over USA in T20 World Cup
-
Lollobrigida skates to first Italian gold of Milan-Cortina Games
-
Barca beat Mallorca to extend Liga lead
-
Gyokeres lifts Arsenal nine clear as Man Utd pile pressure on Frank
US FDA says Pfizer Covid vaccine effective in kids under five
The US Food and Drug Administration (FDA) has said the Pfizer Covid vaccine is safe and effective in children under five, ahead of a meeting to weigh its authorization later this week.
Children under five are the only age group not yet eligible for vaccination in the United States and most countries, a pressing need since rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age," the FDA said in a document posted on its website Sunday.
The agency has called a meeting of experts on June 15 to decide whether to recommend the Pfizer vaccine, given as three shots to children aged six months through four years, as well as the Moderna vaccine, given as two shots to children aged six months through five years.
Pfizer's first two shots are given three weeks apart, then the third is given eight weeks after the second. They are all dosed at three micrograms, as opposed to 30 micrograms the company gives older ages.
Both Pfizer and Moderna had previously posted their results, but the FDA then had to review the data in detail and carry out its own evaluation. It posted a favorable analysis about Moderna on Friday.
Its comments towards Pfizer also appear favorable, based on the levels of infection-blocking antibodies it evoked in trial participants, and a similar side-effect profile to higher age groups. The trial population was around 4,500 children.
A preliminary estimate placed vaccine efficacy at 80.3 percent, but the FDA noted this was based on very few positive cases -- just 10, as opposed to the 21 sought for a more accurate figure.
There are nearly 20 million US children aged four years and under, or six percent of the population. If, as expected, the FDA-appointed experts recommend the two shots, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
J.Oliveira--AMWN